



State of Louisiana
Louisiana Department of Health
Bureau of Health Services Financing

MEMORANDUM

DATE: September 20, 2019
TO: All Louisiana Medicaid Prescribing Providers and Pharmacists
FROM: Jen Steele, Medicaid Director
SUBJECT: Louisiana Fee for Service (FFS) Medicaid Educational Alert for Concurrent Use of Opiates and Antipsychotic Agents

Effective October 1, 2019, the Louisiana Department of Health (LDH) Fee for Service Pharmacy Program in collaboration with the Louisiana Medicaid Drug Utilization Review (LADUR) Board will implement an educational alert at Point of Sale (POS) for concurrent use of opiates and antipsychotic agents.

An incoming claim for an antipsychotic agent will prompt a drug-drug interaction educational alert if there is an active prescription for an opiate on the recipient's file. An incoming claim for an opiate will prompt a drug-drug interaction educational alert if there is an active prescription for an antipsychotic on the recipient's file.

Pharmacy claims for the concurrent use of opiates and antipsychotic agents will post the following educational alert:

**NCPDP reject code 88 (DUR Reject Error) mapped to
EOB 442 (Drug-Drug Interaction).**

This edit will occur at POS as an educational alert. Override provisions are not necessary for an educational alert.

If you have questions about the content of this memo, you may contact the FFS pharmacy help desk by phone at (800) 437-9101.

If you have questions about pharmacy claims billing, you may contact DXC Technology help desk at (800) 648-0790.

FFS Educational Alert for Concurrent Use of Opiates and Antipsychotics

September 20, 2019

Page 2

Please forward this notice to other providers to assist with notification. Your continued cooperation and support of the Louisiana Medicaid Program efforts to coordinate care and improve health are greatly appreciated.

JS/MBW/GJS

**c: Healthy Louisiana Plans
 Melwyn B. Wendt
 DXC Technology**